Press release content from Business Wire. The AP news staff was not involved in its creation.
ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers
April 15, 2021 GMT
SAN DIEGO & SEOUL, South Korea (BUSINESS WIRE) Apr 15, 2021
ROSALIND ®, a software leader in extracting meaningful insights from diverse pools of life science data, today announced that it has partnered with two Seoul-based technology providers to enable a powerful new Single Cell data analysis solution for cancer research scientists in Asia. Geninus, a leading full-service genomics laboratory, will combine the ROSALIND platform with its Celinus™ single cell RNA sequencing service to enable expanded analysis and interpretation of data, as well as seamless sharing and collaboration across labs and geographies. HELiXrUS, a channel partnership company focused on biological big data and multi-omics, played a leading role in establishing this partnership and
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to .
CytoDyn Inc.April 15, 2021 GMT
Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues
VANCOUVER, Washington., April 15, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has executed an exclusive supply and distribution agreement with Chiral Pharma Corporation to supply up to 200,000 vials of leronlimab to critically ill COVID-19 patients in the Philippines under CSP authorizations. This agreement will accelerate the delivery of leronlimab upon an expanded authorization under CSP.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ImmuCell Closes $4,250,000 Equity Financing
ImmuCell CorporationApril 14, 2021 GMT
PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has closed an equity investment.
On April 14, 2021, the Company issued the aggregate of 515,156 common shares at $8.25 per share directly to its largest stockholder (the Pessin family) and several other investors, raising gross proceeds of $4,250,037, with minimal closing costs. These shares have been registered under the Company’s effective shelf registration statement on Form S-3.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Ireland Construction Report 2021, H1 Edition - Industry to Expand by 10.9% in Real Terms - ResearchAndMarkets.com
April 14, 2021 GMT
DUBLIN (BUSINESS WIRE) Apr 14, 2021
The publisher expects the Irish construction industry to expand by 10.9% in real terms in 2021 - up from a decline of 12.7% in 2020
ADVERTISEMENT
The industry’s output was affected by the COVID-19 outbreak and the subsequent lockdown measures imposed to contain the virus’s spread. This has continued to weigh on construction progress and has created supply chain disruptions and project delays.